IP Library › Granted Patent US 8,765,910
Granted Patent B2
US 8,765,910 · App. 12/065,643 · Granted Jul 1, 2014

Method for amidating polypeptides with basic amino acid C-terminals by means of specific endoproteases

Inventors: Sebastian Rissom (Hofheim, DE); Paul Habermann (Frankfurt am Main, DE); Christophe Salagnad (Chatellerault, FR); Frank Zocher (Alsbach-Hahnlein, DE); Laure Landric-Burtin (Athis Mons, FR)
Assignee: Sanofi-Aventis Deutschland GmbH
C07K1/00A61K38/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,765,910
App. No.
12/065,643
Granted
Jul 1, 2014
Kind
B2
Abstract

The invention relates to a method for producing C-terminal amidated dibasic or polybasic peptides, consisting in reacting two peptides in the presence of trypsin biologically active enzymes and, if necessary, in purifying the thus obtainable compounds of formula (I) by means of protein chemistry.

Claims (12)

1. A process for preparing a C-terminally amidated peptide of the formula (AA)-X—NH 2 wherein (AA) is a peptide that comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:4 and wherein X is lysine or arginine; the process comprising reacting a peptide having the amino acid sequence of SEQ ID NO:7 with

(i) H-Arg-NH 2 in a 585:1 molar ratio in the presence of an enzyme having the biological activity of trypsin to produce the C-terminally amidated peptide of SEQ ID NO:4, or

(ii) H-Lys-NH 2 in a 144:1 molar ratio in the presence of an enzyme having the biological activity of trypsin to produce the C-terminally amidated peptide of SEQ ID NO:1,

and the resulting C-terminally amidated peptide is subjected to protein chemical purification.

2. The process as claimed in claim 1 , further comprising

a) expressing a fusion peptide which comprises a peptide having the sequence SEQ ID NO:7 with a recombinant host cell;

b) liberating the peptide having the sequence of SEQ ID NO:7 from said fusion peptide by enzymatic cleavage; and

c) purifying the liberated peptide from step b) and then reacting the purified peptide with H-Arg-NH 2 or H-Lys-NH 2 in the presence of an enzyme having the biological activity of trypsin; and

d) subjecting the resulting peptide to protein chemical purification and isolation.

3. The process as claimed in claim 2 , in which the liberation from the fusion protein takes place by enzymatic cleavage with enterokinase, factor Xa, Genenase, thrombin or trypsin.

4. The process as claimed in claim 3 , in which the fusion protein is expressed in a host/vector expression system selected from the group comprising E. coil, S. carnosus, Salmonella, Bacillus subtilis, Pseudomonas fluorescens, K. lactis, P. pastoris, Schizosaccharomyces pombe and S. cerevisiae.

5. A medicament comprising the C-terminally amidated peptide of SEQ ID NO:4.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2009
From: RISSOM, SEBASTIAN; HABERMANN, PAUL; ZOCHER, FRANK; LANDRIC-BURTIN, LAURE; SALAGNAD, CHRISTOPHE
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 023550/0985 →
Priority Claims (1)
DE 10 2005 046 113 · Sep 27, 2005 · national
Continuity (1)
Related Publication 20100311112A1 · Dec 9, 2010